Various tumours, classically specified as either neuroendocrine or non-neuroendocrine,
contain high numbers of somatostatin receptors, which enable in vivo localization of the …

This article reviews the development of radioimmunoconjugates as a new class of cancer
therapeutics. Numerous conjugates involving different antigen targets, antibody forms …

Detection of tumor foci may be improved by combining the selective tumor-targeting
properties of a monoclonal antibody with the supetior sensitivity and contrast resolutiOnof …

Pretargeting is a multi-step process that first has an unlabeled bispecific antibody (bsMAb)
localize within a tumor by virtue of its anti-tumor binding site (s) before administering a small …

Conclusion: These results suggest that prior chemotherapy or external beam radiation is an
important risk factor for the develop ment of hematological toxicity in radioimmunotherapy …

PURPOSE To assess the performance and the potential clinical impact of a new antibody
imaging agent, CEA-Scan (Immunomedics Inc, Morris Plains, NJ), in 210 presurgical …

ABSTRACT CD16a (FcγRIIIa) mediates the antibody dependent cellular cytotoxicity (ADCC)
and is important for anti-tumor activities of many therapeutic antibodies. Bispecific antibody …

PURPOSE This investigation was undertaken to assess the targeting of established and
occult medullary thyroid cancer (MTC) with radiolabeled monoclonal antibodies (MAbs) …

MEDI-565 (also known as MT111) is a bispecific T-cell engager (BiTE®) antibody in
development for the treatment of patients with cancers expressing carcinoembryonic antigen …

Abstract Chimeric T84. 66 (cT84. 66) is a high-affinity (1.16 x 10 [11] M [-1]) IgG1 monoclonal
antibody (MAb) against carcinoembryonic antigen (CEA). This pilot trial evaluated the tumor …